MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Cathcart who wrote (216)	9/20/1997 11:24:00 AM
From: JOSEPH VON MEISTER	of 1826

A knowlegeable and anonymous comment on MZ's anti-angiogenesis discussion: "I am not aware of any angiogenesis side effect with MGI-114. What I think the author is really saying is that he is having more and more problems with the concept of using anti-angiogenesis as a target for cancer therapy. This approach, of developing anti-angiogenic agents, is being pursued by several large drug companies, without success due to side effects. If you read his comments carefully, I think that is what he is really trying to say but is having difficulty due to his limited English." MGI 114 has caused three biological reactions in the human trials at dose rates well below those that generated a 50% response rate in animals. At 14 mg/M^2 to 20 mg/m^2 we should expect to see increasingly frequent activity in the patients being tested. Go MGI ! JVM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next